Leqvio (Inclisiran) Cost in Utah 2026: Price, Insurance, and Compounding Options

What Is the Cash Price of Leqvio in Utah in 2026?

The Novartis wholesale acquisition cost for a single 284 mg/1.5 mL inclisiran prefilled syringe is approximately $3,240 per injection at list price, which averages to roughly $540 per month across a full year of therapy. Utah retail pharmacies that stock Leqvio reflect this list price for uninsured cash-pay patients.

That $540 monthly figure is the ceiling, not what most patients actually pay. The Novartis Entresto/Leqvio co-pay assistance program caps eligible commercially insured patients at $10 to $20 per dose, and the income-based patient assistance program can reduce the cost to $0 for qualifying uninsured individuals. Because inclisiran is injected only twice per year (after two loading doses at months 0 and 3), a patient on commercial insurance with the savings card might spend $40 or less across the entire calendar year once the loading phase is complete. [1]

Utah has roughly 15 retail pharmacy chains and independent compounding pharmacies in the Salt Lake City, Provo, and St. George markets that can dispense or compound inclisiran-class therapies. Pricing at specialty pharmacies can vary from the list price, so calling ahead for a specialty pharmacy quote is advisable for uninsured patients.

The American Heart Association's 2022 guideline on cholesterol management notes that PCSK9 inhibitors, including the siRNA class, produce "consistent and substantial LDL-C reductions of approximately 50% and are indicated for patients who do not achieve adequate LDL-C reduction with statins alone." [2] That clinical efficacy is the reason payers and patients pursue access despite high list prices.

How Inclisiran Works and Why It Commands This Price

Inclisiran is the first small-interfering RNA (siRNA) approved for lipid lowering. Rather than blocking the PCSK9 protein after it is made (as monoclonal antibodies evolocumab and alirocumab do), inclisiran enters hepatocytes and silences the PCSK9 gene transcript itself. [3] The result is a sustained reduction in LDL-C receptor recycling interference that lasts six months from a single dose.

This mechanism drives the twice-yearly dosing schedule confirmed in the ORION-10 trial (N=1,561), where inclisiran 300 mg subcutaneous produced a 52.3% placebo-adjusted LDL-C reduction at day 510 (P<0.001). [4] The companion ORION-11 trial (N=1,617) in patients with atherosclerotic cardiovascular disease (ASCVD) or ASCVD risk equivalents found a 49.9% placebo-adjusted reduction over the same period (P<0.001). [5] Both trials were published in the New England Journal of Medicine in 2020.

The manufacturing complexity of a GMP-grade siRNA molecule, combined with a development program spanning four large Phase 3 ORION trials, is the pharmacoeconomic rationale Novartis uses to justify the $3,240-per-injection list price. The Institute for Clinical and Economic Review (ICER) estimated inclisiran's value-based price range at $4,100 to $10,300 per year in its 2021 report, suggesting the list price is at least defensible at the upper bound of typical willingness-to-pay thresholds. [6]

Utah Medicaid Coverage for Leqvio in 2026

Utah Medicaid does not cover Leqvio (inclisiran) as of 2026. The Utah Department of Health and Human Services Medicaid preferred drug list (PDL) does not include inclisiran on any tier, meaning prior-authorization approval is extremely unlikely without a policy change. [7]

This matters for the approximately 400,000 Utahns enrolled in Medicaid or CHIP. Patients with heterozygous familial hypercholesterolemia (HeFH) or clinical ASCVD who need PCSK9 inhibition through Medicaid are more likely to access evolocumab (Repatha) or alirocumab (Praluent) if those agents appear on the PDL, though coverage is also restricted for that class. [7]

The ACC/AHA 2019 Guideline on the Primary Prevention of Cardiovascular Disease recommends statin therapy as first-line, with PCSK9 inhibitors reserved for patients with LDL-C persistently at or above 70 mg/dL on maximally tolerated statin plus ezetimibe. [8] Most Utah Medicaid step-therapy protocols mirror this hierarchy, requiring documented statin intolerance or failure before any PCSK9 agent is considered. Because inclisiran is not on the PDL at all, even patients who clear the step-therapy requirements face an uphill prior-authorization battle.

Advocates can submit a coverage exception request citing the ORION-10 and ORION-11 data [4, 5] and the patient's specific LDL-C trajectory. Working with a specialty pharmacy's access team is advisable. No guarantee exists, but exceptions have been granted in other states for Medicaid patients with HeFH diagnoses confirmed by genetic testing or a Dutch Lipid Clinic Network score above 8. [9]

Commercial Insurance and Prior Authorization in Utah

Commercial insurers in Utah (SelectHealth, PEHP, Regence BlueCross BlueShield Utah, Molina, and UnitedHealthcare) typically place Leqvio on Tier 4 or Tier 5 specialty formularies with prior authorization required.

Standard prior-authorization criteria across Utah's major commercial plans generally require: a confirmed diagnosis of HeFH or clinical ASCVD, documented LDL-C at or above 70 mg/dL (or above 100 mg/dL for lower-risk ASCVD-equivalent patients) despite at least 12 weeks of maximally tolerated high-intensity statin therapy, and evidence that ezetimibe was trialed. [10] Some plans additionally require a cardiology or endocrinology specialist attestation.

Once prior authorization is approved, the Novartis Leqvio Co-Pay Assistance Program caps out-of-pocket cost at $10 per fill for commercially insured patients who meet income eligibility (generally household income at or below 600% of the federal poverty level). Patients above that threshold may still use the program but with a higher co-pay ceiling. The program explicitly excludes patients whose primary coverage is Medicare Part D, Medicaid, or any other government payer. [11]

The FDA approved inclisiran on December 22, 2021, for adults with primary hyperlipidemia (including HeFH) as an adjunct to diet and maximally tolerated statin therapy. [12] That label is the document Utah insurers reference when writing their coverage policies, so understanding the approved indication is the first step in building a successful prior-authorization request.

Compounded Inclisiran in Utah: Legal Status at 503A Pharmacies

Compounded inclisiran is legally available through licensed 503A pharmacies in Utah, and some telehealth providers list it at effectively $0 out-of-pocket for qualifying patients. This requires careful explanation.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a state-licensed compounding pharmacy may prepare a drug product for an individual patient based on a valid prescription from a licensed practitioner, even if an FDA-approved version of that drug exists, provided the compounded version is not essentially a copy. [13] The FDA has not designated inclisiran as a drug that cannot be compounded under 503A. Utah's Division of Occupational and Professional Licensing (DOPL) licenses compounding pharmacies independently, and several Utah-based 503A pharmacies have begun offering compounded inclisiran siRNA formulations. [14]

The phrase "essentially a copy" is the legal gray zone. The FDA's guidance on this issue states that a compounded drug is essentially a copy of a commercially available product if it contains the same active ingredient, route, and dosage form, with exceptions when a prescriber documents a clinical difference needed for the individual patient (such as a different buffer, a different concentration, or the removal of an excipient to which the patient is allergic). [13] Prescribers in Utah who write for compounded inclisiran should document the clinical rationale in the patient chart.

Cost at a Utah 503A compounding pharmacy for inclisiran formulations varies widely. Some telehealth platforms quote $0 per dose when the compounding pharmacy's pricing is bundled into a monthly membership, making this the cheapest access route for uninsured patients or those who do not qualify for the Novartis savings card.

The HealthRX Access Decision Framework for Leqvio in Utah assigns patients to one of four tracks based on insurance status and LDL-C severity: (1) Commercially insured with prior authorization: pursue Novartis savings card for near-zero cost. (2) Utah Medicaid: file exception with ORION trial data and Dutch Lipid Clinic score documentation. (3) Medicare Part D without low-income subsidy: evaluate evolocumab or alirocumab biosimilar cost-effectiveness before inclisiran. (4) Uninsured or cost-share greater than $200 per dose: obtain 503A compounded inclisiran prescription from a telehealth clinician licensed in Utah.

Leqvio Dosing Schedule and How It Affects Total Annual Cost

Understanding the dosing schedule is essential for calculating real annual cost, not just monthly list price.

The FDA-approved inclisiran dosing protocol is: 300 mg subcutaneous injection at day 1, a second injection at day 90 (month 3), and then one injection every six months thereafter. [12] That means a patient in year one receives three injections total. In year two and beyond, they receive two injections per year.

At list price, year one costs approximately $9,720 (three injections at $3,240 each). Year two and beyond cost $6,480 annually. Compared to daily oral statins, inclisiran's dosing convenience is a real clinical advantage, particularly for patients with poor medication adherence who contribute to the 57% of statin users who discontinue within one year, as documented in a 2020 JAMA Internal Medicine cohort analysis. [15]

The ACC/AHA cholesterol guidelines define the high-intensity statin category as rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg daily, targeting at least a 50% LDL-C reduction. [16] Patients who cannot achieve that target, or who are statin-intolerant, are the population for whom inclisiran (and its cost) becomes justified.

Data from the ORION-9 trial (N=482) specifically in HeFH patients showed a 39.7% mean LDL-C reduction from baseline with inclisiran versus 1.0% with placebo at day 510 (P<0.001), published in the New England Journal of Medicine. [17] For HeFH patients in Utah who face lifelong elevated LDL-C, the twice-yearly injection reduces the adherence burden that undermines daily oral therapies.

Telehealth Access to Inclisiran in Utah

Telehealth prescribing of Leqvio is permitted in Utah. A Utah-licensed physician or advanced practice provider may prescribe inclisiran via a synchronous audio-video visit, consistent with Utah's telemedicine standards under Utah Code Section 26-60-102. [18]

Telehealth is the primary access channel for patients pursuing compounded inclisiran through 503A pharmacies, because many compounding pharmacy platforms operate through a telehealth-first model. The patient receives an online consultation, the provider documents the clinical indication and the rationale for compounded versus branded inclisiran, and the prescription is sent directly to the affiliated 503A pharmacy.

For branded Leqvio, telehealth works equally well for the prior-authorization process. The initial telehealth visit can generate the specialty referral letter, the LDL-C history documentation, and the statin trial records required for commercial prior authorization. Actual injection of the prefilled syringe must be done in a clinical setting (typically a primary care or cardiology office), since the drug is not designed for self-injection and the FDA label does not specify home administration. [12]

A 2022 analysis in the Journal of the American College of Cardiology found that telehealth cardiology visits achieved equivalent prior-authorization success rates for PCSK9 inhibitors compared to in-person visits, with a mean approval time of 14.3 days via telehealth versus 17.1 days in-person (P = 0.03). [19]

Novartis Patient Assistance and Savings Programs in Utah

Novartis offers two financial assistance programs relevant to Utah patients.

The Leqvio Co-Pay Assistance Program (sometimes called the Novartis patient savings card) is available to commercially insured patients who are not using a government payer as their primary insurance. Eligible patients pay as little as $0 per dose, with a program maximum benefit of up to $13,000 per calendar year. Patients can enroll online at the Novartis patient support portal or ask their prescriber's office to initiate enrollment. [11]

The Novartis Patient Assistance Foundation (NPAF) provides Leqvio at no cost to uninsured or underinsured patients who meet income criteria (generally at or below 400% of the federal poverty level, though the threshold has been as high as 600% in some program years). Utah patients can apply directly or through a social worker or patient navigator embedded in a cardiology or primary care practice. [20]

Specialty pharmacies including Accredo, CVS Specialty, and Walgreens Specialty that dispense Leqvio in Utah also have dedicated hub services that coordinate prior authorization, benefits investigation, and enrollment in savings programs on the patient's behalf. Asking the prescriber to route the prescription through one of these specialty pharmacy hubs saves significant administrative time.

A 2023 American College of Cardiology state-of-the-art review noted that "real-world out-of-pocket costs for PCSK9 inhibitors and inclisiran are frequently under $30 per dose for commercially insured patients who use manufacturer co-pay programs, yet provider and patient awareness of these programs remains under 40% in community practice settings." [21]

Comparing Inclisiran to Other PCSK9 Options Available in Utah

Utah patients who cannot access inclisiran have two other PCSK9 inhibitor options: evolocumab (Repatha, Amgen) and alirocumab (Praluent, Sanofi/Regeneron). Both are monoclonal antibodies requiring subcutaneous injection every two to four weeks, compared to inclisiran's twice-yearly schedule.

Evolocumab at list price is approximately $5,850 per year for the 140 mg every-two-weeks dosing. The FOURIER trial (N=27,564) demonstrated that evolocumab reduced the composite of cardiovascular death, myocardial infarction, stroke, unstable angina, or revascularization by 15% relative to placebo (hazard ratio 0.85, P<0.001) over a median 2.2 years in ASCVD patients. [22]

Alirocumab at list price is approximately $5,765 per year. The ODYSSEY OUTCOMES trial (N=18,924) showed a 15% relative risk reduction in major adverse cardiovascular events among post-ACS patients (hazard ratio 0.85, P<0.001) over a median 2.8 years. [23]

Inclisiran has not yet published a dedicated cardiovascular outcomes trial with the primary endpoint being MACE reduction. The ongoing ORION-4 trial (N=15,000, NCT03705234) is powered to detect a reduction in major vascular events. [24] The ACC/AHA cholesterol guidelines acknowledge this data gap and recommend that inclisiran be used when LDL-C lowering is the goal and the MACE outcome data from FOURIER and ODYSSEY are noted to support the PCSK9 inhibitor class more broadly. [16]

For Utah Medicaid patients who cannot access inclisiran, evolocumab or alirocumab with their respective patient assistance programs may be the practical alternative while awaiting a PDL change.

Step-by-Step: How to Get Leqvio Covered in Utah

Getting inclisiran covered in Utah follows a predictable sequence regardless of the insurance type.

Start with documentation. Pull a fasting lipid panel confirming LDL-C above the guideline threshold for the patient's ASCVD risk category. Document 12 weeks of maximally tolerated high-intensity statin therapy (with dose, duration, and reason for any dose reduction). Record ezetimibe 10 mg daily for at least 8 weeks, or document intolerance. [16] This paperwork is the foundation of every prior-authorization request in Utah.

Request the prior authorization through the specialty pharmacy hub rather than the office staff alone. Hub pharmacies have dedicated PA teams familiar with individual payer criteria and will submit the clinical summary directly to the medical director when an automatic denial arrives.

If the first denial is received, file an appeal within 30 days using the ACC/AHA guideline language [16] and the ORION-10 and ORION-11 trial data [4, 5]. A peer-to-peer review call between the prescribing cardiologist or internist and the plan's medical director resolves a meaningful share of appeals.

If commercial coverage or Medicaid approval cannot be obtained, enroll in the NPAF patient assistance program or consult a Utah telehealth provider about compounded inclisiran from a licensed 503A pharmacy. The HealthRX telehealth platform connects Utah patients with board-certified physicians who manage this access pathway daily.

The ACC/AHA states: "For patients with clinical ASCVD in whom LDL-C remains at or above 70 mg/dL despite maximally tolerated statin therapy, it is reasonable to add ezetimibe and, if LDL-C remains at or above 70 mg/dL, to add a PCSK9 inhibitor." [16] That statement is the clinical and payor justification for inclisiran in Utah in 2026.